发明申请
US20080207705A1 Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists
审中-公开
杂芳基咪唑衍生物作为大麻素CB1受体拮抗剂
- 专利标题： Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists
- 专利标题（中）： 杂芳基咪唑衍生物作为大麻素CB1受体拮抗剂
-
申请号： US12037986申请日： 2008-02-27
-
公开(公告)号： US20080207705A1公开(公告)日： 2008-08-28
- 发明人: Jinhwa LEE , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn , Suk Ho Lee
- 申请人： Jinhwa LEE , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn , Suk Ho Lee
- 申请人地址： KR Yongin-si
- 专利权人： Green Cross Corporation
- 当前专利权人： Green Cross Corporation
- 当前专利权人地址： KR Yongin-si
- 主分类号： A61K31/4245
- IPC分类号： A61K31/4245 ; C07D413/04 ; A61K31/433 ; A61K31/426 ; A61P3/04 ; A61K31/421 ; C07D417/04
摘要：
A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
信息查询
